Key Points
-
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds.
-
The sale represented 8% of the insider’s direct equity holdings in the company, as reported in the Form 4.
-
The transaction was executed under a Rule 10b5-1 trading plan established on August 15, 2025, and marks the final sale under this schedule.
- 10 stocks we like better than UroGen Pharma ›
Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (NASDAQ:URGN) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing.
Transaction summary
MetricValueTransaction value$400,000Shares sold10,000Post-transaction shares (directly held)119,763Post-transaction value$4.82 million
Key questions
- What was the mechanism for this transaction?The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025, which provides for automated execution and represents the concluding transaction of that plan’s schedule.
- What is the scale of the insider’s remaining direct investment?Mark Schoenberg continues to hold 119,763 ordinary shares directly.
- What financial context does UroGen Pharma Ltd. present at this valuation?The biotechnology company, which develops solutions for urothelial and specialty cancers, reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million.
- How does the current market capitalization compare to the transaction level?The disposition occurred with the company’s market capitalization at $2.0 billion, following a period of performance where shares were priced at $40.23 as of the July 9, 2026 market close.
Company Overview
MetricValueShare Price (as of market close 2026-07-09)$40.23Market Capitalization$2.0 billionRevenue (TTM)$140.5 millionNet Income (TTM)-$133.2 million
Company Snapshot
- UroGen Pharma develops and commercializes innovative solutions for urothelial and specialty cancers, with primary revenue sources including Zusduri, a sustained-release mitomycin formulation for non-muscle invasive bladder cancer, and RTGel, a proprietary reverse thermal gelation hydrogel technology platform.
- The company operates a commercial-stage biotechnology business model focused on bringing novel therapeutic formulations to market, generating revenue through product sales while continuing to invest in research and development for pipeline expansion.
- UroGen’s primary customers are urology and oncology specialists, with target markets encompassing patients with non-muscle invasive bladder cancer and other urothelial malignancies requiring adjuvant chemotherapy and specialized treatment modalities.
UroGen Pharma is a commercial-stage biotechnology company with a $2 billion market capitalization, demonstrating significant growth momentum with a one-year stock appreciation of 191.31%. The company has achieved meaningful revenue scale at $140.5 million TTM while maintaining a focused pipeline strategy centered on proprietary drug delivery technologies for underserved oncology indications. UroGen’s competitive advantage derives from its proprietary RTGel platform technology and its established commercial infrastructure for specialty cancer therapeutics, positioning the company as a differentiated player in the niche urothelial cancer treatment market.
What this transaction means for investors
First, it’s important to note that this was the final trade in a 10b5-1 plan Schoenberg set almost a year ago, so the timing was locked in long before Schoenberg could know how the firm was necessarily going to be performing. He still holds nearly 120,000 shares worth close to $4.8 million, and a chief medical officer keeping a stake that size while the company’s newest drug is inflecting isn’t sending any signal about the science.
The launch of Zusduri, UroGen’s new bladder cancer therapy, is what matters here, and it’s going well. UroGen’s first quarter revenue jumped 152% to $51 million, as a result of the launch, which brought in $29.2 million and more than doubled quarter over quarter after a permanent insurance billing code kicked in. CEO Liz Barrett called January’s J-code “a major inflection point,” and unique prescribers jumped to 256 from 102 in a single quarter. More recently, the firm announced that the FDA cleared its investigational new drug application for UGN-501, enabling a planned Phase 1 study in patients with non-muscle invasive bladder cancer. It’s expected to begin in the fourth quarter.
Should you buy stock in UroGen Pharma right now?
Before you buy stock in UroGen Pharma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UroGen Pharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $395,679!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!*
Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
